Landos Biopharma (LABP) Announces Tim M. Mayleben to Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. CRWV
2. NVDA
3. SPY
4. BAC
5. BLK
6. CAT
7. AA
8. RKLB
9. RXRX
10. NOW

Go back to Landos Biopharma (LABP) Announces Tim M. Mayleben to Board

Landos Biopharma (LABP) and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

May 17, 2021 7:11 AM EDT

Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan and Macau) and select Asian markets. Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohns disease (CD) and... More